Clinical Trials Logo

Clinical Trial Summary

This study aimed to evaluate the impact of specialized discharge education on the daily life activities and quality of life of geriatric patients hospitalized in COVID-19 wards. The motivation behind this study stems from the vulnerability of elderly patients during the COVID-19 pandemic and the necessity of tailored education to support their daily life activities and enhance their quality of life after discharge. The primary objective of this article is to determine the specific type of specialized discharge education that geriatric patients in COVID-19 wards require to improve their ability to sustain daily life activities and enhance their quality of life. The central idea of this study is that providing specialized discharge education to geriatric patients in COVID-19 wards can result in improvements in their daily life activities and quality of life. The main findings of the study demonstrate a significant enhancement in daily life activities and quality of life among patients who received specialized discharge education. These individuals exhibited increased independence in mobility, improved performance in daily life activities, and reported an overall improvement in their quality of life. These findings underscore the significance of specialized discharge education for geriatric patients hospitalized in COVID-19 wards and highlight its positive impact on their health outcomes and quality of life.

Clinical Trial Description

Purpose: This research aimed to determine the impact of specialized discharge training on the daily living activities and quality of life of geriatric patients admitted to the COVID-19 ward. Materials and Methods: A quasi-experimental study was conducted on geriatric patients admitted to a training and research hospital's COVID-19 ward between April 1 and July 1, 2022. A control group of 40 individuals and a study group of 40 individuals, both meeting the inclusion criteria, were established. Research data were collected using the Descriptive Features Form, Katz Index of Independence in Activities of Daily Living, and SF-12 Quality of Life Scale. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05867485
Study type Interventional
Source Kilis 7 Aralik University
Status Completed
Phase N/A
Start date April 1, 2022
Completion date July 1, 2022

See also
  Status Clinical Trial Phase
Suspended NCT04901676 - Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia Phase 3
Not yet recruiting NCT04534478 - Oral Prednisone Regimens to Optimize the Therapeutic Strategy in Patients With Organizing Pneumonia Post-COVID-19 Phase 4
Active, not recruiting NCT05002517 - Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab Phase 3
Completed NCT05008393 - Efficacy of PJS-539 for Adult Patients With COVID-19. Phase 2
Completed NCT04569877 - GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia Phase 2
Not yet recruiting NCT05286255 - Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias Phase 1
Completed NCT05035589 - The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
Recruiting NCT05042063 - Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
Recruiting NCT04615429 - Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19 Phase 2
Completed NCT05047653 - RALE Versus CORADS/CT-Severity Score in COVID-19
Active, not recruiting NCT05047016 - Study to Evaluate the Dynamic Consent Model Based on the Blockchain-based Clinical Trial Platform METORY N/A
Active, not recruiting NCT05033847 - Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above Phase 2
Completed NCT05504655 - N-Acetylcysteine as an Adjuvant Therapy in Critically Ill COVID-19 Patients:
Active, not recruiting NCT05035524 - A Randomized Controlled Trial to Investigate The Role of Adjuvant Inhalable Sodium Bicarbonate Solution 8.4% in Treatment of COVID-19 N/A
Completed NCT05065879 - Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes Phase 4
Withdrawn NCT04390217 - LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia Phase 2
Withdrawn NCT04460105 - Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia Phase 1
Suspended NCT04901689 - Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation Phase 3
Not yet recruiting NCT05094596 - Effect of Montelukast Therapy on Clinical Course, Pulmonary Function, and Mortality in Patients With COVID-19 Phase 4
Withdrawn NCT05166915 - Respiratory COVID-19: A Randomized, Sham-Controlled Study N/A